“…Several prognostic factors have been identified in relapsed AML, such as time to relapse, early response to salvage therapy, French-American-British (FAB) and cytogenetics subtypes of blast cells alike in acute lymphoblastic leukemia [4,5]. Moreover, modern diagnostic tools, such as whole exome sequencing analyses, are revealing new potentially actionable mutations [2,4].…”